Kiniksa Pharmaceuticals International (KNSA) Change in Account Payables (2017 - 2026)

Kiniksa Pharmaceuticals International's Change in Account Payables history runs 10 years deep, the most recent figure standing at $22.3 million for Q1 2026.

• Quarterly Change in Account Payables rose 35812.9% year-over-year to $22.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.3 million (up 723.84% YoY) and the FY2025 annual result came in at $142000.0, up 102.25% from the prior year.
• Change in Account Payables was $22.3 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from -$4.1 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $22.3 million in Q1 2026 and bottomed at -$6.5 million in Q1 2023.
• A 5-year average of $1.3 million and a median of $62000.0 in 2025 frame the typical range for Change in Account Payables.
• Annual changes were most pronounced in 2023 — Change in Account Payables sank 529.57% — and 2026, when it jumped 35812.9%.
• Kiniksa Pharmaceuticals International's Change in Account Payables stood at $6.4 million in 2022, then gained by 12.5% to $7.2 million in 2023, then tumbled by 186.87% to -$6.3 million in 2024, then soared by 34.4% to -$4.1 million in 2025, then soared by 640.17% to $22.3 million in 2026.
• Business Quant data shows KNSA's Change in Account Payables at $22.3 million in Q1 2026, -$4.1 million in Q4 2025, and -$2.7 million in Q3 2025.